Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than five years. Factors underlining long-term survivorship in PDAC are not well understood. Therefore, we aimed to identify the key players in the tumor immune microenvironment (TIME) associated with long-term survivorship in PDAC patients.MethodsThe immune-related gene expression profiles of resected PDAC tumors of patients who survived and remained recurrence-free of disease for ≥36 months (long-term survivors, n=10) were compared to patients who had survived ≤6 months (short-term survivors, n=10) due to tumor recurrence. Validation was performed by the spatial protein expression profile of immune cells using the GeoMx™ Digital Spatial Profiler....
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease. The only option for curativ...
Abstract Purpose: Although abundant myeloid cell populations in the pancreatic ductal adenocarcinom...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
The aggressive biology and treatment refractory nature of pancreatic ductal adenocarcinoma (PDAC) si...
B-cell responses are emerging as critical regulators of cancer progression. In this study, we invest...
Pancreatic ductal adenocarcinoma is a lethal disease with limited treatment options and poor surviva...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease. The only option for curativ...
Abstract Purpose: Although abundant myeloid cell populations in the pancreatic ductal adenocarcinom...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background and aimOnly 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than f...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to single-agent immunotherapies. To...
The aggressive biology and treatment refractory nature of pancreatic ductal adenocarcinoma (PDAC) si...
B-cell responses are emerging as critical regulators of cancer progression. In this study, we invest...
Pancreatic ductal adenocarcinoma is a lethal disease with limited treatment options and poor surviva...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease. The only option for curativ...
Abstract Purpose: Although abundant myeloid cell populations in the pancreatic ductal adenocarcinom...